AG08C5
PGNMi001-A
General
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 1-4 |
| Ethnicity | Asian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Family history | hiPSC derived from healthy male donor AG08498 fibroblast cells (https://catalog.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=AG08498&Product=CC) |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
46, XY
|
External Databases (Donor) |
|
| BioSamples | SAMN03120540 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | No |
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell line name | AG08498 |
| Source cell type |
Synonyms
|
| Source cell origin | |
| Age of donor (at collection) | 1-4 |
| Collected in | 1985 |
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Lentivirus) |
| Genes | |
| Is the used vector excisable? |
Unknown |
| Absence of reprogramming vector(s)? |
Unknown |
| Reprogramming vectors silenced? | |
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | HiPS colonies were picked about 4 to 6 weeks after infection based on ES cell-like morphology. |
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
TrypLE
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
Other medium:
Base medium: StemMACS iPS-Brew XF (Miltenyi)
Main protein source: Serum concentration: % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| TRA 1-60 |
Yes |
|
||||
| TRA 1-81 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|||||
| NANOG |
Yes |
|
||||
| SOX2 |
Yes |
|
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Morphology pictures
Cell morphology of the clone, 4 days after thawing and grown in StemMACSTM iPS Brew XF Medium (Miltenyi Biotec)
Differentiation Potency
In vitro directed differentiation
| Marker | Expressed |
| FOXA2 |
Yes |
| SOX17 |
Yes |
In vitro directed differentiation
| Marker | Expressed |
| TBXT |
Yes |
| HAND1 |
Yes |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.